Thus, to reactivate production of fetal hemoglobin, patients with SCD or TDT were infused with CRISPR-Cas9 edited hematopoietic stem and progenitor cells (HSPCs) that were mutated at the BCL11A locus. This evidence concerns the gene BCL11A and Schnyder corneal dystrophy.